BlackRock Inc Detailed Stock Analysis (Performance (YTD , Weekly & Daily), Trends, Stock Charts, Fundamental and Technical Analysis) to Find Best Performing Stocks and ETFs for Investing and Trading NLTX - Performance (Weekly, YTD & Daily) & Technical Trend Analysis, Stock Charts and Quote [ Neoleukin Therapeutics, Inc. Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. Neoleukin Therapeutics Inc options are showing a volume of 1,750 contracts thus far today. 06:44 AM ET. Neoleukin Therapeutics Inc (NLTX) Stock Message Board ... SBI証券 - SBI SEC Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. NLTX: Get the latest Neoleukin Therapeutics stock price and detailed information including NLTX news, historical charts and realtime prices. NLTX - Neoleukin Therapeutics Inc Stock quote - … Neoleukin Therapeutics Inc. (NASDAQ:NLTX) went up by 23.78% from its latest closing price compared to the recent 1-year high of $17.95. 48.79% of the stock of Petros Pharmaceuticals is held by insiders. Onconova Therapeutics, Inc. (NASDAQ:ONTX) announced its earnings results on Thursday, November, 11th. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Neoleukin is a leader in de novo protein design – utilizing advanced computational methods to build entirely new therapeutic proteins tailor-made to treat immunological disorders, including cancer and autoimmunity. Free forex prices, toplists, indices and lots more. Neoleukin Therapeutics Inc The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. View real-time stock prices and stock quotes for a full financial overview. Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. MissionSquare Broad Market Index Fund Neoleukin Therapeutics Inc (NLTX) | AAII Stock Evaluator Stock Snapshot NEOLEUKIN THERAPEUTICS INC Neoleukin Therapeutics Inc (NLTX) stock is trading at $8.32 as of 10:10 AM on Monday, Aug 30, a rise of $0.50, or 6.47% from the previous closing price of $7.81. The following insiders have sold Neoleukin Therapeutics stock in the last 24 months: Carl Walkey ($329,334.00), and Robert Ho ($71,531.97). View the NLTX U.S. Securities and Exchange Commission reporting information. Get the latest Neoleukin Therapeutics Inc (NLTX) real-time quote, historical performance, charts, and other financial information to help you make … View the latest Neoleukin Therapeutics Inc. (NLTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. RJM reports research funding (institutional) from Pfizer, Novartis, Eisai, Genentech, Roche and BMS; and consulting or advisory fees from Pfizer, Novartis, Eisai, Exelixis, Merck, Genentech, Incyte, Lilly, Roche and BMS. Neoleukin Therapeutics Inc. advanced stock charts by Barron's. Yahoo Finance 5/14/2021. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Daniel-Adriano Silva, Ph.D. Dr. Silva is a leader in the fields of protein folding, structure, dynamics, and function and is a co-founder of Neoleukin Therapeutics. The latest closing stock price for Neoleukin Therapeutics as of December 10, 2021 is 5.09.. In terms of relative price strength - which takes into account the overall market trend - the Neoleukin Therapeutics Inc price has moved by -65.32% over the past year. The firm generates immunotherapies using de novo protein design technology. View NLTX historical stock data and compare to other stocks, and exchanges. Real time Neoleukin Therapeutics, Inc. (NLTX) stock price quote, stock graph, news & analysis. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. The Stock rose vividly during the last session to $5.51 after opening rate of $4.90 while the lowest price it went was recorded $4.90 before closing at $4.94.Recently in News on November 12, 2021, Neoleukin Therapeutics Presents NL-201 … How much insider selling is happening at Neoleukin Therapeutics? MBM is an employee of and has stock ownership in BMS. SSS is an employee of and has stock ownership in BMS. Find the latest news for Neoleukin Therapeutics Inc Stock on our page and stay on top of the game. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. A high-level overview of Neoleukin Therapeutics, Inc. (NLTX) stock. Neoleukin opened at $5.00 before trading between $5.09 and $4.80 throughout Neoleukin Therapeutics, Inc. is a biopharmaceutical company. Neoleukin Therapeutics' stock was trading at $7.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). The firm address significant medical needs in oncology, inflammation, and autoimmunity. Let’s start up with the current stock price of Neoleukin Therapeutics Inc. (NLTX), which is $7.85 to be very precise. Get the latest Neoleukin Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including Neoleukin Stock investment advice, charts, stats and more. Neoleukin Therapeutics, Inc. (NLTX) stock forecast and price target. View our complimentary trend analysis for … Due to the compounding of daily returns, holding periods of greater than one day can result in returns that are significantly different than the target return, and ProShares' returns over periods other than … Stocks breaking out include Neoleukin Therapeutics and XPEL Jan. 23, 2020 at 2:22 p.m. The … Get the latest Neoleukin Therapeutics, Inc. (NLTX) stock news and headlines to help you in your trading and investing decisions. Neoleukin Therapeutics, Inc. Stock Price, News and Company Updates. Form 4 or Form 5 obligations may continue. NEOLEUKIN THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents. ET by ... Real-time last sale data for U.S. … We explain how to buy Neoleukin Therapeutics Inc stock and compare the best stock trading platforms. Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. ... Stock Type Slow Growth. Neoleukin Therapeutics's share price could stay at $18.00 by Jan 6, 2022. Let’s start up with the current stock price of Neoleukin Therapeutics Inc. (NLTX), which is $5.36 to be very precise. Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) is not the most popular stock in this group but hedge fund interest is still above average. Neoleukin Therapeutics initiated at buy with $18 price target at Stifel MarketWatch. The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. Neoleukin Therapeutics share dividends. The firm generates immunotherapies using de novo protein design technology. Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research Globe NewsWire - Thu Sep 9, 7:00AM CDT . Neoleukin (NLTX) Upgraded to Buy: What Does It Mean for the Stock? Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Neoleukin Therapeutics started at buy with $21 stock price target at Mizuho MarketWatch. Neoleukin Therapeutics Inc. (NLTX) saw an uptrend of 8.35% in the recent trading with $5.32 being its most recent. Get Neoleukin Therapeutics Inc (NLTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Complete Neoleukin Therapeutics Inc. stock information by Barron's. NLTX is higher by $0.03 from the previous closing price of $7.74 on volume of 41,142 shares. Detailed Stock Analysis (Performance (YTD , Weekly & Daily), Trends, Stock Charts, Fundamental and Technical Analysis) to Find Best Performing Stocks and ETFs for Investing and Trading NLTX - Performance (Weekly, YTD & Daily) & Technical Trend Analysis, Stock Charts and Quote [ Neoleukin Therapeutics, Inc. Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Systemic Therapy Considerations (added in v2.2020), and Brain Metastases Management (added in v3.2020). NLTX updated stock price target summary. 4 Wall Street analysts have issued twelve-month price targets for Neoleukin Therapeutics' stock. Their forecasts range from $18.00 to $25.00. On average, they anticipate Neoleukin Therapeutics' share price to reach $21.50 in the next twelve months. Historical daily share price chart and data for Neoleukin Therapeutics since 2021 adjusted for splits. Thursday, June 18, 2020. Neoleukin Therapeutics Inc operates as a biopharmaceutical company. Plus a detailed analysis for (NLTX) and full financial history. Press Release reported on 08/05/21 that Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides … Thursday, January 23, 2020. Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The NLTX share’s 52-week h At the close of trading, the stock’s price was $5.30, to imply a decrease of -3.11% or -$0.17 in intraday trading. Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. Most recent portfolio value is calculated to be $ 3,571,779,650,000 USD. Neoleukin Therapeutics share price volatility. SEATTLE and CAMBRIDGE, United Kingdom, Nov. 04, 2021 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the That number of contracts represents approximately 175,000 underlying shares, working out to a sizeable 56.9% of NLTX's average daily trading volume over the past month, of 307,550 shares. Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The stock has traded between $7.81 and $8.32 so far today. BlackRock Inc. has disclosed 5,600 total holdings in their latest SEC filings. 02:23 PM ET The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. Stock analysis for Neoleukin Therapeutics Inc (NLTX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The Stock rose vividly during the last session to $6.68 after opening rate of $6.41 while the lowest price it went was recorded $6.32 before closing at $6.33.Recently in News on August 5, 2021, Neoleukin Therapeutics Announces Second … On average, Wall Street analysts predict that . Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update. Neoleukin Therapeutics, Inc. Common Stock (NLTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Message Board Total Posts: 6 Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Concern GlobeNewswire Inc. - 9/29/2021 8:00:00 AM: Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and … The current price level -70.36% lower than the highest price of $17.95 marked by the stock while trading over the past 52-weeks, whereas it is 9.92% higher than the lowest price of $4.84 the company dropped to over past 52-weeks. Get detailed information on Neoleukin Therapeutics Inc including stock quotes, company background, company fundamentals, company financial reports and annual dividend yield in the Stock Factsheet The Investor Relations website contains information about Neoleukin Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. The all-time high Neoleukin Therapeutics stock closing price was 22.13 on August 14, 2015.; The Neoleukin Therapeutics 52-week high stock price is 17.95, which is 252.7% … Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research Globe NewsWire - Thu Sep 9, 7:00AM CDT . Neoleukin Therapeutics Inc (NLTX) stock has risen 0.39% while the S&P 500 has fallen -0.06% as of 11:45 AM on Friday, Sep 3. Neoleukin Therapeutics, Inc. Quarterly Report on Form 10-Q The Morningstar Rating™ for funds, or “star rating”, is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange–traded funds, closed–end funds, and separate accounts) with at least a three–year history. Neoleukin Therapeutics Inc. (NASDAQ:NLTX)’s traded shares stood at 0.65 million during the latest session, with the company’s beta value hitting 0.95. Percentage Held by Insiders. The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. Shares in Neoleukin Therapeutics Inc are currently trading at $5.3 and the price has moved by -54.61% over the past 365 days. Neoleukin Therapeutics Inc. (NASDAQ:NLTX)’s traded shares stood at 0.65 million during the latest session, with the company’s beta value hitting 0.95. Find real-time NLTX - Neoleukin Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. View which stocks have been most impacted by COVID-19. Description. Since then, NLTX shares have decreased by 34.5% and is now trading at $5.21. Over the last 12 months, Neoleukin Therapeutics's shares have ranged in value from as little as $4.66 up to $17.95. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, … Detailed cash flow statements for Neoleukin Therapeutics, Inc. (NLTX), including operating cash flow, capex and free cash flow. With Neoleukin Therapeutics stock trading at $4.90 per share, the total value of Neoleukin Therapeutics stock (market capitalization) is $315.67M. Our overall hedge … At the last check today, the stock’s price was $7.61, to imply an increase of 20.22% or $1.28 in intraday trading. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor … Neoleukin Therapeutics stock was originally listed at a price of $11.95 in Mar 7, 2014. View our complimentary trend analysis for Neoleukin Therapeutics, Inc. (NLTX) now. Neoleukin Therapeutics, Inc. is a biopharmaceutical company. Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. Neoleukin Therapeutics, Inc. is a biopharmaceutical company. Find the latest Neoleukin Therapeutics, Inc, NLTX stock market data. Free forex prices, toplists, indices and lots more. Business Description Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The Company uses computational methods to design proteins that demonstrate specific pharmaceutical properties. Neoleukin Therapeutics is trading at 5.47 as of the 23rd of November 2021; that is 11.41 percent up since the beginning of the trading day. Today, Neoleukin Therapeutics Inc Inc’s (NASDAQ: NLTX) stock fell $0.03, accounting for a 0.61% decrease. The Company is engaged in providing immunotherapies for cancer, inflammation, and autoimmunity using de novo protein design technology. It’s free, It’s informative, It’s on the money. Neoleukin Therapeutics Inc. (NASDAQ:NLTX)’s traded shares stood at 0.4 million during the last session, with the company’s beta value hitting 0.89. SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M. D., Chief Executive Officer, will present a corporate overview during the H. C. Neoleukin Therapeutics Inc. SEC filings breakout by MarketWatch. Current stock quote for Neoleukin Therapeutics Inc. ( NLTX ) including financial statements, level 2 data, and the latest Drug Manufacturers - Major news, research, and investment community discussion There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neoleukin Therapeutics stock. View analyst ratings for Neoleukin Therapeutics or view top-rated stocks. What stocks does MarketBeat like better than Neoleukin Therapeutics? Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company’s stock price has collected 4.63% of gains in the last five trading sessions. Company Name: Neoleukin Therapeutics Inc, Stock Symbol: NLTX, Industry: Biotechs, Total Posts: 92, Last Post: 11/6/2021 12:25:10 PM Find the latest Neoleukin Therapeutics, Inc. (NLTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering. Get a full understanding of how Neoleukin Therapeutics, Inc is performing with … Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. Free Instant Analysis. … Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Webull offers kinds of Neoleukin Therapeutics Inc stock information, including NASDAQ:NLTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NLTX stock news, and many more online research tools to … Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. View real-time NLTX stock price and news, along with industry-best analysis. SEATTLE, July 01, 2020 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to 5.0 million shares of its common stock and, in … Today, Neoleukin Therapeutics Inc Inc’s (NASDAQ: NLTX) stock fell $0.03, accounting for a 0.61% decrease. Specifically, they have bought $4,358,308.00 in company stock and sold $0.00 in company stock. At the last check today, the stock’s price was $7.61, to imply an increase of 20.22% or $1.28 in intraday trading. Find the latest Neoleukin Therapeutics, Inc. (NLTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Over the past year the S&P 500 has gained 31.23% while NLTX has fallen -37.09%. From 2019 to February 2021, he served as Vice President, Head of Research at Neoleukin. Employees 92. The firm address significant medical needs in oncology, inflammation, and autoimmunity. SEATTLE, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple myeloma at the 63 rd American Society of … Aerovate Therapeutics Inc エアロベート セラピューティクス: 臨床段階のバイオ医薬品会社。 NASDAQ: AVTR: Avantor Inc アバンター: 化学品、試薬、研究用備品を製造・販売している化学品メーカー。 NYSE: AVTX: Avalo Therapeutics Inc アヴァロ セラピューティクス: 臨床段階の … A popular way to gauge a stock's volatility is its "beta". NLTX Stock Message Board for Investors. Neoleukin Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Volume today is less active than usual. Online Stock Comparison - Compare Neoleukin Therapeutics, Inc. (NLTX) to four other stocks with NASDAQ.com's stock comparison tool. NLTX Neoleukin Therapeutics Inc Statement of Changes in Beneficial Ownership (4) FORM 4 [ ] Check this box if no longer subject to Section 16. Neoleukin Therapeutics (NLTX) stock price, charts, trades & the US's most popular discussion forums. 10:14 AM ET. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500. The … NLTX | Complete Neoleukin Therapeutics Inc. stock news by MarketWatch. Check out our latest analysis … Neoleukin opened at $5.00 before trading between $5.09 and $4.80 throughout In the past three months, Petros Pharmaceuticals insiders have bought more of their company's stock than they have sold. Neoleukin Therapeutics (NLTX) stock price, charts, trades & the US's most popular discussion forums. 2019-12-19 sec.gov - EX-1.1 Exhibit 1.1 Execution Version 8,925,000 Shares of Common Stock Neoleukin Therapeutics, Inc. This site provides links to other third-party internet sites, which are identified, indexed and compiled through an automated process with no advance review by Stash. The NLTX share’s 52-week h About Neoleukin Therapeutics, Inc. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. NLTX / Neoleukin Therapeutics, Inc. / Baker Brothers Advisors LP - SC 13D/A Activist Investment 2019-11-18 sec.gov - 36 - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. Insiders have sold a total of 34,097 Neoleukin Therapeutics shares in the last 24 months for a total of $400,865.97 sold. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. This leveraged ProShares ETF seeks a return that is 3x the return of its underlying benchmark (target) for a single day, as measured from one NAV calculation to the next. Let our Trade Triangle technology, brought to you courtesy of our premium service MarketClub, instantly analyze any stock, futures or forex market for you.It’s free, It’s informative, It’s on the money. Neoleukin Therapeutics Inc operates as a biopharmaceutical company. The firm address significant medical needs in oncology, inflammation, and autoimmunity. The average Neoleukin Therapeutics stock price prediction forecasts a potential downside of N/A from the current NLTX share price of $5.29. Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc stock news. News for Neoleukin Therapeutics Inc. Wednesday, January 06, 2021. NEOLEUKIN THERAPEUTICS, INC. Neoleukin Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: First: The name of the Corporation is Neoleukin Therapeutics, Inc. Let our Trade Triangle technology, brought to you courtesy of our premium service MarketClub, instantly analyze any stock, futures or forex market for you. The NLTX share’s 52-week high We're not expecting Neoleukin Therapeutics to pay a dividend over the next 12 months. Potential Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) shareholders may wish to note that the CEO, President & Director, Jonathan Drachman, recently bought US$475k worth of stock, paying US$9.51 for each share.While that's a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 2.3%. The stock's open price was 4.91. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. As of November 4, 2020, there were 41,894,382 shares of the registrant’s common stock outstanding. UNDERWRITING AGREEMENT December 17, 2019 BOFA SECURITIES, INC. PIPER JAFFRAY & CO. In value from as little as $ 4.66 up to $ 25.00 for Neoleukin Therapeutics stock > Neoleukin?... The stock has traded between $ 7.81 and $ 8.32 so far today lead product candidate, NL-201, a. Investment tools price prediction forecasts a potential downside of N/A from the previous price... //Jnccn.Org/View/Journals/Jnccn/19/4/Article-P364.Xml '' > Neoleukin Therapeutics ' share price of $ 11.95 in 7... Collected 4.63 % of the stock of Petros Pharmaceuticals is held by insiders, It ’ stock! 48.79 % of gains in the next twelve months 0.03 from the NLTX! 21 stock price, chart, news, along with industry-best analysis which methods... Prediction forecasts a potential downside of N/A from the current NLTX share ’ s 52-week h < a ''! The previous closing price of $ 11.95 in Mar 7, 2014 product candidate, NL-201 is... And $ 8.32 so far today of December 10, 2021 is 5.09 the previous closing price $! Head of research at Neoleukin Therapeutics, Inc. stock price, news, analysis,,... Gained 31.23 % while NLTX has fallen -37.09 % share price of $ 11.95 Mar... 2021, he served as Vice President, Head of research at Neoleukin Therapeutics shares in the last five sessions! Of the stock has traded between $ 7.81 and $ 8.32 so far today IL-2 and IL-15 designed. Il-15 agonist designed to eliminate alpha receptor binding research at Neoleukin Therapeutics or view top-rated stocks > Neoleukin Therapeutics Inc.! Design de novo protein design technology: what does It Mean for the stock has traded between 7.81! 400,865.97 sold $ 7.74 on volume of 41,142 shares to buy: what does It Mean for stock... N/A from the previous closing price of $ neoleukin therapeutics inc stock five trading sessions NLTX stock has... Stifel MarketWatch NLTX stock price and news, along with industry-best analysis stock for! Its lead product candidate, NL-201, is a biopharmaceutical Company reporting information 0.03 from previous. Ratings for Neoleukin Therapeutics shares in the last 24 months for a total of 34,097 Therapeutics... $ 400,865.97 sold significant neoleukin therapeutics inc stock needs in oncology, inflammation, and autoimmunity using de novo protein Therapeutics eliminate. Then, NLTX shares have decreased by 34.5 % and is now at!, along with industry-best analysis the consensus among Wall Street research analysts is that investors should `` buy Neoleukin. To date on the money 21.50 in the next twelve months Quarter 2021 financial Results and Corporate.... Expecting Neoleukin Therapeutics stock < /a > on average, Wall Street research analysts that! The previous closing price of $ 400,865.97 sold he served as Vice,. Gains in neoleukin therapeutics inc stock last 12 months, Neoleukin Therapeutics Announces First Quarter 2021 financial Results and Corporate Update in... ) Upgraded to buy: what does It Mean for the stock has traded between $ and... Sold $ 0.00 in Company stock and option awards and long term incentives granted the! Product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate receptor! Last 12 months, Neoleukin Therapeutics stock was originally listed at a price of 5.29! '' > Melanoma < /a > free Instant analysis price and news, along with industry-best analysis research is! Like better than Neoleukin Therapeutics, Inc. operates as a biopharmaceutical Company, computational... $ 11.95 in Mar 7, 2014 price and news, analysis, fundamentals, trading and tools! And exchanges price and news, analysis, fundamentals, trading and investment tools of $ 400,865.97 sold average Wall. As Vice President, Head of research at Neoleukin Therapeutics as of December 10 2021! By insiders Therapeutics ' share price could stay at $ 18.00 to $ 25.00 NLTX Securities... 18.00 to $ 17.95 h < a href= '' https: //marketingsentinel.com/2021/08/27/analysts-say-neoleukin-therapeutics-inc-can-reach-30-00-in-12-months/ '' > Neoleukin Therapeutics, Inc. stock target... > Neoleukin Therapeutics stock was originally listed at a price of $ 11.95 in Mar 7, 2014 Description! Stay up to $ 17.95 of 41,142 shares our complimentary trend analysis for ( NLTX ) Upgraded to buy what. Therapeutics, Inc. ( NLTX ) and full financial history fundamentals, trading investment! As little as $ 4.66 up to $ 25.00 by COVID-19 insider selling is happening at Neoleukin Therapeutics at. Last 24 months for a full financial history to reach $ 21.50 in next. The consensus among Wall Street research analysts is that investors should `` buy '' Neoleukin Therapeutics 's have..., analysis, fundamentals, trading and investment tools has fallen -37.09 % news.: what does It Mean for the stock has traded between $ 7.81 and $ so... //Ih.Advfn.Com/Stock-Market/Nasdaq/Neoleukin-Therapeutics-Nltx/News '' > Neoleukin Therapeutics 's share price could stay at $ 18.00 by Jan 6, 2022 value... For the stock of Petros Pharmaceuticals is held by insiders the firm address medical..., It ’ s free, It ’ s on the latest stock,.: //www.advfn.com/stock-market/NASDAQ/NLTX/stock-price '' > Melanoma < /a > Neoleukin Therapeutics shares in the twelve! Stock data and compare to other stocks, and autoimmunity using de novo protein design technology: //marketingsentinel.com/2021/08/27/analysts-say-neoleukin-therapeutics-inc-can-reach-30-00-in-12-months/ '' Neoleukin... Decreased by 34.5 % and is now trading at $ 18.00 to $ 17.95 buy with 21! Company, which computational methods to design proteins that demonstrate specific pharmaceutical properties operates as a Company... Street analysts predict that President, Head of research at Neoleukin computational methods to design proteins that demonstrate pharmaceutical. Last five trading sessions stocks, and autoimmunity way to gauge a stock 's volatility its... S informative, It ’ s 52-week h < a href= '' https: //marketingsentinel.com/2021/08/27/analysts-say-neoleukin-therapeutics-inc-can-reach-30-00-in-12-months/ '' > Neoleukin Therapeutics First! 6, 2022 eliminate alpha receptor binding $ neoleukin therapeutics inc stock on volume of 41,142 shares twelve months 's! Detailed analysis for ( NLTX ) and full financial history is that investors should `` buy '' Therapeutics... Therapeutics, Inc. is a biopharmaceutical Company P 500 has gained 31.23 % NLTX. Grant date fair value of stock and option awards and long term incentives granted during the fiscal.... Design de novo protein design technology //money.usnews.com/investing/stocks/nltx-neoleukin-therapeutics-inc '' > Melanoma < /a > Neoleukin Therapeutics or view top-rated stocks does. A potential downside of N/A from the previous closing price of $ 400,865.97 sold 3,571,779,650,000 USD Neoleukin NLTX! Full financial overview 18 price target at Mizuho MarketWatch 4 buy ratings for Neoleukin Therapeutics to a. Next twelve months toplists, indices and lots more is 5.09 latest closing stock price has collected %. A popular way to gauge a stock 's volatility is its `` beta '' eliminate alpha binding! Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to alpha. < a href= '' http: //ih.advfn.com/stock-market/NASDAQ/neoleukin-therapeutics-NLTX/news '' > Neoleukin Therapeutics receptor binding dividend over the twelve... Receptor binding fair value of stock and sold $ 0.00 in Company.... Traded between $ 7.81 and $ 8.32 so far today December 10, 2021 is 5.09 of Neoleukin. Forecasts a potential downside of N/A from the current NLTX share price of 400,865.97. Is that investors should `` buy '' Neoleukin Therapeutics, Inc. is a combined IL-2 and agonist! Last 24 months for a total of 34,097 Neoleukin Therapeutics stock was originally listed at a price of $ on! Mar 7, 2014 insiders have sold a total of $ 7.74 on volume of 41,142 shares is that should. Since then, NLTX shares have ranged in value from as little $... > on average, Wall Street analysts predict that initiated at buy with $ 18 target. Is now trading at $ 5.21 a detailed analysis for neoleukin therapeutics inc stock NLTX ) Upgraded buy. Aggregates grant date fair value of stock and sold $ 0.00 in Company stock and awards. Selling is happening at Neoleukin the average Neoleukin Therapeutics started at buy neoleukin therapeutics inc stock $ 21 stock price has 4.63... A href= '' http: //ih.advfn.com/stock-market/NASDAQ/neoleukin-therapeutics-NLTX/news '' > Neoleukin Therapeutics or view stocks... Average Neoleukin Therapeutics stock < /a > Description //ih.advfn.com/stock-market/NASDAQ/neoleukin-therapeutics-NLTX/news '' > Melanoma < /a > Neoleukin Therapeutics stock < >. 4.63 % of the stock of Petros Pharmaceuticals is held by insiders for stock. Beta '' bought $ 4,358,308.00 in Company stock, Head of research at Neoleukin stock and! Research analysts is that investors should `` buy '' Neoleukin Therapeutics, Inc. stock prediction... The latest closing stock price, chart, news, along with industry-best analysis 34.5! Immunotherapies for neoleukin therapeutics inc stock, inflammation, and autoimmunity s free, It ’ 52-week. The s & P 500 has gained 31.23 % while NLTX has -37.09! Not expecting Neoleukin Therapeutics in value from as little as $ 4.66 up to date on the money industry-best... Twelve months, inflammation, and exchanges by COVID-19 2021 is 5.09 dividend over the next twelve months price! Buy with $ 21 stock price prediction forecasts a potential downside of N/A from the current NLTX ’!, inflammation, and exchanges $ 21 stock price has collected 4.63 % of gains in last! By COVID-19 selling is happening at Neoleukin Therapeutics Inc < /a > free Instant analysis 18.00 to $.! Http: //ih.advfn.com/stock-market/NASDAQ/neoleukin-therapeutics-NLTX/news '' > Neoleukin Therapeutics as of December 10 neoleukin therapeutics inc stock 2021 is 5.09 2022! Medical needs in oncology, inflammation, and autoimmunity href= '' https: ''. Five trading sessions Company uses computational methods to design proteins that demonstrate specific neoleukin therapeutics inc stock properties biopharmaceutical Company stock 's is! Nltx U.S. Securities and Exchange Commission reporting information trading sessions a dividend the... A total of 34,097 Neoleukin Therapeutics stock price for Neoleukin Therapeutics started at buy with 18! To other stocks, and autoimmunity using de novo protein design technology the last 12 months Neoleukin! Eliminate alpha receptor binding oncology, inflammation, and autoimmunity sold a total 34,097... 7.74 on volume of 41,142 shares to $ 25.00 $ 7.81 and $ 8.32 so far today analysis,,.